AD-230

AD-230 is a fixed-dose combination (FDC) drug candidate developed by Addpharma Inc., a subsidiary of Yuhan Corporation, for the treatment of chronic liver disease. Classified as an "incrementally modified drug" (IMD) in South Korea, AD-230 combines biphenyl dimethyl dicarboxylate (BDD) and ursodeoxycholic acid (UDCA). BDD is a synthetic analogue of schisandrin C that acts as a hepatoprotectant, primarily by lowering elevated serum transaminase levels (ALT/AST) and protecting hepatocytes from oxidative damage. UDCA is a hydrophilic bile acid that provides cytoprotective, choleretic, and immunomodulatory effects, helping to stabilize cell membranes and promote bile flow. In clinical development, AD-230 is being evaluated in comparative pharmacokinetic and safety studies against AD-2301, which serves as the reference drug (likely the multi-component hepatoprotectant Godex). The development of AD-230 aims to provide a streamlined therapeutic option for patients with chronic hepatitis and other liver pathologies.

Other names

AD-230 + AD-2301BDD/UDCA combination